PT Kimia Farma Tbk plans to divest 38 assets consisting of land and buildings, with a total book value of Rp 2.152 trillion. This initiative is part of a restructuring program designed to strengthen liquidity and ensure business continuity amid challenges in the post-pandemic pharmaceutical industry.

The company’s board of directors stated that the asset transfer is intended to generate fresh funds to support operations and business development.

“This asset divestment plan is a key strategy for the company to balance profitability and liquidity, particularly in light of rising lending interest rates,” wrote management in a disclosure to the Indonesia Stock Exchange (BEI), quoted Sunday (28/9/2025).

38 Properties Targeted for Sale Across Key Cities in Indonesia

The assets planned for divestment are spread across major cities, including Jakarta, Bandung, Medan, Semarang, and Manado, as well as in the industrial area of Cikarang.

According to the company’s consolidated financial report as of June 30, 2025, the value of these assets is equivalent to 65.35% of Kimia Farma’s total equity, which was recorded at Rp 3.29 trillion.

Shareholders to Vote in November 3 Extraordinary General Meeting

As the transaction value exceeds 50% of the company’s equity, it qualifies as a material transaction and requires shareholder approval through an Extraordinary General Meeting of Shareholders (RUPSLB), scheduled for November 3, 2025.

If the plan is not approved, a re-submission may only occur at the earliest 12 months after the meeting. The company emphasized that the asset transfer will comply with legal provisions, through public auction, limited offer, or direct appointment.

Kimia Farma Reduces Losses by 58.10% as of June 2025

Kimia Farma reported varied financial performance in the first half of 2025. Net sales reached Rp 4.36 trillion, marking a 16.19% decrease from Rp 5.21 trillion in the same period the previous year.

Cost of goods sold fell by 22.72% to Rp 2.80 trillion. Gross profit decreased slightly by 1.16% from Rp 1.57 trillion to Rp 1.49 trillion.

Operating expenses were reduced by 14.31% to Rp 1.49 trillion. Other income dropped to Rp 7.02 billion from Rp 105.21 billion, while foreign exchange losses narrowed to Rp 475.28 million from Rp 841.07 million.

Loss attributable to the owners of the parent company was reduced by 58.10%, from Rp 226.78 billion to Rp 95.01 billion.

Company Equity Declines Slightly While Liabilities Rise

The company’s equity declined to Rp 3.29 trillion as of June 2025 from Rp 3.42 trillion in December 2024.

Total liabilities increased to Rp 11.6 trillion from Rp 11.53 trillion over the same period.

Kimia Farma reported total assets of Rp 14.97 trillion as of June 30, 2025, compared to Rp 14.96 trillion in December 2024. The company held Rp 232.66 billion in cash and cash equivalents.

PHOTO: ANTARA/BIOFARMA

This article was created with AI assistance.